Key result
Rapid olanzapine escalation linked to neuroleptic malignant syndrome resolving with drug withdrawal and bromocriptine.
Case Report (n=1)
No
Highlights that neuroleptic malignant syndrome, typically associated with typical antipsychotics, can rarely occur with the atypical antipsychotic olanzapine.
NMS vigilance advised during olanzapine titration; extends atypical associations but leaves incidence and causality open.
Neuroleptic malignant syndrome (NMS) is a life-threatening adverse effect usually seen with typical antipsychotic drugs. Rarely, NMS can occur with atypical antipsychotics also. A 19-year-old male diagnosed as a case of acute and transient psychotic disorder developed NMS, following the treatment with an atypical antipsychotic, olanzapine 20 mg/day. The patient was diagnosed NMS, an offending agent olanzapine was immediately withdrawn, and prompt treatment by maintaining hydration and giving bromocriptine produced recovery.
No takes yet. Share an insight, caveat, or question.
Saha et al. (2017) conducted a case report in Acute and transient psychotic disorder (n=1). Olanzapine was evaluated on Development of Neuroleptic Malignant Syndrome. A 19-year-old male developed neuroleptic malignant syndrome following rapid dose escalation of olanzapine to 20 mg/day, which resolved upon drug withdrawal and treatment with bromocriptine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: